Literature DB >> 6605385

OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells.

K Welte, E Platzer, C Y Wang, E A Rinnooy Kan, M A Moore, R Mertelsmann.   

Abstract

We studied IL 2 production and proliferation induced by OKT3 mitogenic monoclonal antibody in the OKT8+ T cell subset. OKT3 antibody induced IL 2 production and proliferation in OKT8+ cells in a typical time-dependent manner: maximal IL 2 levels were found in 24 hr culture supernatants; maximal proliferation was found on day 3. OKT3 antibody was mitogenic over a wide range of concentrations (0.125 to 500 ng/ml). The presence of OKT8 antibody (greater than or equal to 100 ng/ml) in these cultures resulted in almost complete inhibition of IL 2 production and proliferation. Kinetic studies demonstrate that OKT8 antibody suppresses both IL 2 production and response to exogenous IL 2 in OKT8+ cells when added within the first 2 hr of culture. After 14 to 20 hr of culture, addition of OKT8 only blocks IL 2 production but not the IL 2 response of activated OKT8+ cells. The specificity of inhibition by OKT8 antibody of OKT3 mitogenicity on OKT8+ cells was confirmed by the failure of Leu-I and OKT4 antibody to produce the same effect and by the lack of inhibition by OKT8 antibody of OKT3-induced IL 2 production and proliferation in OKT4+ cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605385

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  The role of class I histocompatibility antigens in the regulation of T-cell activation.

Authors:  J D Dasgupta; K Cemach; D P Dubey; E J Yunis; D B Amos
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

2.  Interactions of CD4+ and CD8+ human T lymphocytes from malaria-unprimed donors with Plasmodium falciparum schizont stage.

Authors:  C Roussilhon; M Agrapart; C Behr; P Dubois; J J Ballet
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

3.  Transient deficiency of peripheral blood accessory cells in supporting T cell mitogenesis in patients suffering from chronic idiopathic thrombocytopenic purpura after intravenous gammaglobulin treatment.

Authors:  L M Larocca; N Maggiano; G Leone; M Piantelli; D Scribano; P Musiani
Journal:  Blut       Date:  1985-07

Review 4.  Pharmacological modification of immunoregulatory activity of lymphocytes: facts and potential.

Authors:  S H Polmar
Journal:  Surv Immunol Res       Date:  1984

5.  Activation of human T lymphocytes: differential effects of CD3- and CD8-mediated signals.

Authors:  Y Samstag; F Emmrich; T Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

Authors:  J J Fung; A J Demetris; K A Porter; S Iwatsuki; R D Gordon; C O Esquivel; R Jaffe; A Tzakis; B W Shaw; T E Starzl
Journal:  Nephron       Date:  1987       Impact factor: 2.847

7.  Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset.

Authors:  C Saltini; J R Spurzem; J J Lee; P Pinkston; R G Crystal
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

8.  Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome.

Authors:  H W Murray; K Welte; J L Jacobs; B Y Rubin; R Mertelsmann; R B Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

9.  Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals.

Authors:  M Suthanthiran; P S Williams; S D Solomon; A L Rubin; K H Stenzel
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Tyrosine phosphorylation of CD19 in pre-B and mature B cells.

Authors:  N J Chalupny; S B Kanner; G L Schieven; S F Wee; L K Gilliland; A Aruffo; J A Ledbetter
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.